AbbVie Breaks Ground on $70M Biologics Expansion in Massachusetts

NORTH CHICAGO, Ill. - AbbVie (NYSE: ABBV) has officially broken ground on a $70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, marking a major step in the company’s long-term U.S. manufacturing strategy. The expanded facility will reinforce the company’s position as a leader in biologics research, development and production for critical therapies in immunology and oncology.

The project is part of AbbVie’s previously announced commitment to invest more than $10 billion in U.S. capital projects, focusing on expanding domestic manufacturing capabilities to meet growing global demand.

The Worcester-based ABC campus, long recognized as a center of excellence for biologics, will see the addition of new manufacturing areas along with a three-story building that includes laboratory, warehouse and office space. A key component of the expansion is the expedited transfer of select oncology products from Europe to the United States, strengthening domestic supply chain resilience.

“For more than three decades, ABC has been at the forefront of scientific innovation and biologics manufacturing,” said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. “This investment will further expand AbbVie’s biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide.”

Strengthening U.S. Manufacturing Footprint

AbbVie employs 28,000 people nationwide, with more than 2,000 employees in Massachusetts. The expansion will create additional jobs at the Worcester site and broaden the company’s U.S. operations footprint, which spans 11 manufacturing locations and supports over 6,000 American jobs.

The company noted that increased biologics capacity will help meet rising needs for current and future immunology and oncology treatments, both domestically and globally.

Commitment to Innovation and Workforce Growth

The Worcester investment underscores AbbVie’s strategy to bring more high-value manufacturing to U.S. soil while supporting its research and development pipeline. The new laboratory and operational spaces will enhance the company’s ability to accelerate development timelines, improve supply chain responsiveness, and strengthen its presence in the Northeast biotech corridor.

About AbbVie

AbbVie’s mission centers on discovering and delivering innovative medicines that address serious health challenges of today while preparing for those of tomorrow. Its core therapeutic areas include immunology, oncology, neuroscience, eye care, and Allergan Aesthetics.

Originally reported by Bio Space.